Medical therapy for ischemic stroke

Clinical Neuropharmacology

Volumn 19, Issue 2, 1996, Pages 101-128

  Silver, Brian ^a   Weber, Johannes ^a   Fisher, Marc ^a,b  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b Med Center of Central Massachusetts   (United States)

Author keywords

Cytoprotective; Stroke; Thrombolysis

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR BLOCKING AGENT; 6 NITRO 7 SULFAMOYLBENZO[F]QUINOXALINE 2,3 DIONE; ACETYLSALICYLIC ACID; ALTEPLASE; ANCROD; ANISTREPLASE; ANTIOXIDANT; APTIGANEL; CALCIUM CHANNEL BLOCKING AGENT; CALPASTATIN; CLENTIAZEM; CLOPIDOGREL; CYCLOHEXIMIDE; DIHYDROPYRIDINE DERIVATIVE; DIZOCILPINE; FIBRINOLYTIC AGENT; GANGLIOSIDE; GLUTAMATE RECEPTOR ANTAGONIST; GROWTH FACTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PROPENTOFYLLINE; PROUROKINASE; PYRAZOLOPYRIMIDINE DERIVATIVE; SEROTONIN ANTAGONIST; STREPTOKINASE; TICLOPIDINE; TISSUE PLASMINOGEN ACTIVATOR; UNINDEXED DRUG; UROKINASE; WARFARIN;

BLEEDING; BRAIN ANGIOGRAPHY; CAROTID ENDARTERECTOMY; CLINICAL TRIAL; FIBRINOLYTIC THERAPY; HEART INFARCTION; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; META ANALYSIS; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIMARY PREVENTION; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW; STROKE;

EID: 0029924471     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002826-199619020-00001     Document Type: Review

References (273)

1. Astrup J, Siesjo BK, Symon L. Thresholds in cerebral ischemia - the ischemic penumbra. Stroke 1981;12:723-5.
2. Jones TH, Morawetz RB, Crowell RM, et al. Thresholds of focal cerebral ischemia in awake monkeys. J Neurosurg 1981;54:773-82.
3. Siesjo BK. Cell damage in the brain: a speculative synthesis. J Cereb Blood Flow Metab 1981;1:155-85.
4. Siesjo BK, Bengtsson F. Calcium fluxes, calcium antagonists and calcium related pathology in brain ischemia, hypoglycemia and spreading depression: a unifying hypothesis. J Cereb Blood Flow Metab 1989;9:127-40.
5. Siesjo BK, Agardh CD, Bengtsson F. Free radicals and brain damage. Cerebrovasc Brain Metab Rev 1989;1:165-211.
6. Flamm ES, Demopoulos HB, Seligman ML, Poser RG, Ransohoff J. Free radicals in cerebral ischemia. Stroke 1978;9:445-7.
7. Bartus RT, Baker KL, Heiser AD, et al. Postischemic administration of AK275, a calpain inhibitor, provides substantial protection against focal ischemic brain damage. J Cereb Blood Flow Metab 1994;14:537-44.
8. Bartus RT, Hayward NJ, Elliot PJ, et al. Calpain inhibitor AK295 protects neurons from focal brain ischemia. Effects of postocclusion intraarterial administration. Stroke 1994;25:2265-70.
9. Allen GS, Ahn HS, Preziosi TJ, et al. Cerebral artery spasm - a controlled trial of nimodipine in patients with subarachnoid hemorrhage. N Engl J Med 1983;308:619-24.
10. Philippen J, Grob R, Dagreou F, Guggiari M, Rivierez M, Viars P. Prevention of vasospasm in subarachnoid haemorrhage. A controlled study with nimodipine. Acta Neurochir 1986;82:110-14.
11. Petruk KC, West M, Mohr G, et al. Nimodipine treatment in poor-grade aneurysm patients. Results of a multicenter double-blind placebo-controlled trial. J Neurosurg 1988;68:505-17.
12. Pickard JD, Murray GD, Illingworth R, et al. Effect of oral nimodipine on cerebral infarction and outcome after subarachnoid haemorrhage: British aneurysm nimodipine trial. Br Med J 1989;298:636-42.
13. Ohman J, Heiskanen O. Effect of nimodipine on the outcome of patients after aneurysmal subarachnoid hemorrhage and surgery. J Neurosurg 1988;69:683-6.
14. Jan M, Buchheit F, Tremoulet M. Therapeutic trial of intravenous nimodipine in patients with established cerebral vasospasm after rupture of intracranial aneurysms. Neurosurgery 1988;23:154-7.
15. Desbourdes JM, Ades PE, Guggiari M. Nimodipine intraveineuse dans le traitement curatif du vasospasme cerebral secondaire aux hemorrhagies meningees par rupture anevrysmale: etude comparative multicenfrique. Agressologie 1989;30:438-40.
16. Mohr JP, Orgogozo JM, Harrison MJG, et al. Meta-analysis of oral nimodipine trials in acute ischemic stroke. Cerebrovasc Dis 1994;4:197-203.
17. Heiss WD, Holthoff V, Pawlik G, Neveling M. Effect of nimodipine on regional cerebral glucose metabolism in patients with acute ischemic stroke as measured by positron emission tomography. J Cereb Blood Flow Metab 1990;10:127-32.
18. Norris JW, LeBrun LH, Anderson BA (The Canwin Study Group). Intravenous nimodipine in acute ischaemic stroke. Cerebrovasc Dis 1994;4:194-6.
19. Wahlgren NG, MacMahon DG, DeKeyser J, Indredavik B, Ryman T, for the INWEST study group. Intravenous Nimodipine West European Stroke Trial (INWEST) of nimodipine in the treatment of acute ischaemic stroke. Cerebrovasc Dis 1994;4:204-10.
20. Kaste M, Fogelholm R, Erila T, et al. A randomized, double-blind placebo-controlled trial of nimodipine in acute ischemic hemispheric stroke. Stroke 1994;25:1348-53.
21. Gelmers HJ, Hennerici M. Effect of nimodipine on acute ischemic stroke. Pooled results from five randomized trials. Stroke 1990;21(12 suppl):IV81-4.
22. Wiernsperger N, Gygax P, Hofmann A. Calcium antagonist PY 108-068. Demonstration of its efficacy in various types of experimental brain ischemia. Stroke 1984;15:679-85.
23. Sauter A, Rudin M. Calcium antagonists reduce the extent of infarction in rat middle cerebral artery occlusion model as determined by quantitative magnetic resonance imaging. Stroke 1986;17:1228-34.
24. Vorstrup S, Andersen A, Blegvad N, Paulson OB. Calcium antagonist (PY 108-068) treatment may further decrease flow in ischemic areas in acute stroke. J Cereb Blood Flow Metab 1986;6:222-9.
25. Oczkowski WJ, Hachinski VC, Bogousslavsky J, Barnett HJM, Carruthers SG. A double-blind, randomized trial of PY-108-068 in acute ischemic cerebral infarction. Stroke 1989;20:604-8.
26. Azcona A, Lataste X. Isradipine in patients with acute ischaemic cerebral infarction: an overview of the ASCLEPIOS programme. Drugs 1990;40(suppl 2):52-7.
27. Lataste X, Maurer W, Whitehead J, and the ASCLEPIOS study group. Application of sequential methods to clinical trial in stroke: the ASCLEPIOS Study. 2nd World Congress of Stroke, Washington, D.C., 1992.
28. Kikkawa K, Yamauchi R, Suzuki T, et al. Effects of clentiazem on cerebral ischemia induced by carotid artery occlusion in stroke-prone spontaneously hypertensive rats. Stroke 1994;25:474-80.
29. Foster AC, Wong EH. The novel anti-convulsant MK-801 binds to the activated state of the N-methyl-D-aspartate receptor in rat brain. Br J Pharmacol 1987;91:403-9.
30. Wong BY, Coulter DA, Choi DW, Prince DA. Dextrorphan and dextromethorphan, common antitussives, are antiepileptic and antagonize N-methyl-D-aspartate in brain slices. Neurosci Lett 1988;85:261-6.
31. Nowak L, Bregestovski P, Ascher P, Herbet A, Prochiantz A. Magnesium gates glutamate-activated channels in mouse central neurones. Nature 1984;307:462-5.
32. Peters S, Koh J, Choi DW. Zinc selectively blocks the action of N-methyl-D-aspartate on cortical neurons. Science 1987;236:589-93.
33. Kochhar A, Zivin JA, Lyden PD, Mazzarella V. Glutamale antagonist therapy reduces neurologic deficits produced by focal central nervous system ischemia. Arch Neurol 1988;45:148-53.
34. Ozyurt E, Graham DI, Woodruff GN, McColloch J. Protective effect of the glutamate antagonist, MK-801, in focal cerebral ischemia in the cal. J Cereb Blood Flow Metab 1988:8:138-43.
35. Park CK, Nehls DG, Graham DI, Teasdale GM, McCulloch J. The glutamate antagonist MK-801 reduces focal ischemic damage in the rat. Ann Neurol 1988;24:543-51.
36. Park CK, Nehls DG, Graham DI, Teasdale GM, McCulloch J. Focal cerebral ischemia in the cat: treatment with the glutamate antagonist MK-801 after induction of ischemia. J Cereb Blood Flow Metab 1988;8:757-62.
37. Buchan AM, Xue D, Slivka A, Zhang C, Hamilton J, Gelb A. MK-801 increases cerebral blood flow in a rat model of temporary focal cortical ischemia. Soc Neurosci Abstr 1989;15:804.
38. Swan SH, Meldrum BS, Early, not late, administration of NMDA receptor antagonists protects against selective ischemic cell loss. [Abstract]. J Cereb Blood Flow Metab 1989;9(suppl 1):S558.
39. Gill R, Foster AC, Woodruff GN. MK-801 is neuroprotective in gerbils when administered during the post-ischemic period. Neuroscience 1988;25:847-55.
40. Gill R, Foster AC, Woodruff GN. Neuroprotective actions of MK-801 in rat global ischemia model. [Abstract]. J Cereb Blood Flow Metab 1989;9(suppl 1):S629.
41. Fleischer J, Tateishi A, Drummond JC, et al. Effects of MK-801 upon neurological outcome following cardiac arrest in cats. Anesthesiol Rev 1988;15:102-3.
42. Park CK, Nehls DG, Teasdale GM, McCulloch J. Effect of the NMDA antagonist MK-801 on the local cerebral blood flow in focal cerebral ischemia in the rat. J Cereb Blood Flow Metab 1989;9:617-22.
43. Koek W, Woods JH, Winger GD. MK-801, a proposed noncompetitive antagonist of excitatory amino acid transmission produces phencyclidine-like behavioral effect in pigeons, rats and rhesus monkeys. J Pharmacol Exp Ther 1988;245:969-74.
44. Bucan AM, Lesiuk H, Barnes KA, Li H, Smith KE, Xue D. AMPA antagonists: do they hold more promise for clinical trials than NMDA antagonists? Stroke 1993;24(suppl 1):I148-52.
45. George CP, Goldberg MP, Choi DW, Steinberg GK. Dextromethorphan reduces neocortical ischemic neuronal damage in vivo. Brain Res 1988;440:375-9.
46. Steinberg GK, George CP, DeLaPaz R, Shibata DK, Gross T. Dextromethorphan protects against cerebral injury following transient focal ischemia in rabbits. Stroke 1988;19:1112-18.
47. Steinberg GK, Saleh J, Kunis D. Delayed treatment with dextromethorphan and dextrorphan reduces cerebral damage after transient focal ischemia. Neurosci Lett 1988;89:193-7.
48. Steinberg GK, Saleh J, Kunis D, DeLaPaz R, Zarnegar SR. Protective effect of N-methyl-D-aspartate antagonists after focal cerebral ischemia in rabbits. Stroke 1989;20:1247-52.
49. Albers GW, Saenz RE, Moses JA, Choi DW. Safety and tolerance of oral dextromethorphan in patients at risk for brain ischemia stroke. Stroke 1991;22:1075-7.
50. Albers GW, Atkinson RP, Kelley RE, Rosenbaum MD, on behalf of the Dextrorphan Study Group. Safety, tolerability, and pharmacokinetics of the N-methyl-D-aspartate antagonist dextrorphan in patients with acute stroke. Stroke 1995;26:254-8.
51. Minematsu K, Fisher M, Li L, et al. Effects of a novel NMDA antagonist on experimental stroke rapidly and quantitatively assessed by diffusion-weighted MRI. Neurology 1993;43:397-403.
52. Meadows ME, Fisher M, Minematsu K. Delayed treatment with a noncompetitive NMDA antagonist. CNS 1102, reduces infarct size in rats. Cerebrovasc Dis 1994;4:26-31.
53. Fisher M, for CNS 1102-003 Investigators. Cerestat (CNS 1102). a non-competitive NMDA antagonist in ischemic stroke patients: dose escalating safety study. [Abstract]. Cerebrovasc Dis 1994;4:245.
54. McDonald JW, Silverstein FS, Johnston MV. Magnesium reduces N-methyl-D-aspartate (NMDA)-mediated brain injury in perinatal rats. Neurosci Lett 1990;109:234-8.
55. Izumi Y, Roussel S, Pinard E, Seylaz J. Reduction of infarct volume by magnesium after middle cerebral artery occlusion in rats. J Cereb Blood Flow Metab 1991;11:1025-30.
56. 2+ administered up to twenty-four hours following reperfusion prevents ischemic damage of the CA1 neurons in the rat hippocampus. Neuroscience 1991;44:335-41.
57. Koh J, Choi DW. Zinc alters excitatory amino acid neurotoxicity on cortical neurons. J Neurosci 1988;8:2164-71.
58. Choi DW, Yokoyarna M, Koh J. Zinc neurotoxicity in cortical cell culture. Neuroscience 1988;24:67-79.
59. Lehmann J, Hutchison AJ, McPherson SE, et al. CGS 19755, a selective ,and competitive N-methyl-D-aspartate-type excitatory amino acid receptor antagonist. J Pharmacol Exp Ther 1988;246:65-75.
60. Whitten JP, Baron BM, Muench D, Miller F, White HS, McDonald IA. (R)-4-oxo-5-phosphononorvaline: a new competitive glutamate antagonist at the NMDA receptor complex. J Med Chem 1990;33:2961-3.
61. Boast CA, Gerhardt SC, Pastor G, Lehmann J, Etienne PE, Liebman JM. The N-methyl-D-aspartate antagonists CGS 19755 and CPP reduce ischemic brain damage in gerbils. Brain Res 1988;442:345-8.
62. Simon R, Shiraishi K. N-methyl-D-aspartate antagonist reduces stroke size and regional glucose metabolism. Ann Neurol 1990;27:606-11.
63. Grotta J for the CGS19755 Study Group. Safety and tolerability of the glutamate antagonist CGS 19755 in acute stroke patients. [Abstract]. Stroke 1994;25:255.
64. Clark WM, Coull BM, for the CGS19755 Study Group. Randomized trial of CGS 19755, a glutamate antagonist, in acute ischemic stroke. [Abstract]. Stroke 1994;44(suppl 2):A270.
65. Hasegawa Y, Fisher M, Baron BM, Metcalf G. The competitive NMDA antagonist, MDL 100-453 reduces infarct size after experimental stroke. Stroke 1994;25:1241-6.
66. 3H]MK-801 to the N-methyl-D-aspartate receptor-ion channel complex by L-glutamate, glycine and polyamines. J Neurochem 1988;51:830-6.
67. Kleckner NW, Dingledine R. Requirements for glycine in activation of NMDA receptors expressed in Xenopus oocytes. Science 1988;241:835-7.
68. Johnson JW, Ascher P. Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature 1987;325:529-31.
69. Gotti B, Benavides J, MacKenzie ET, Scatton B. The pharmacotherapy of focal cortical ischemia in the mouse brain. Brain Res 1990;522:290-307.
70. Poignet H, Nowicki JP, Scatton B. Lack of neuroprotective effect of some sigma ligands in a model of focal cerebral ischemia in the mouse. Brain Res 1992;596:320-4.
71. Fisher M. Potentially effective therapies for acute ischemic stroke. Eur Neurol 1995;35:3-7.
72. Choi DW. Methods for antagonizing glutamate neurotoxicity. Cerebrovasc Brain Metab Rev 1990;2:105-47.
73. Keinanen K, Wisden W, Sommer B, Werner P. A family of AMPA-selective glutamate receptors. Science 1990;249:556-60.
74. Koh J, Goldberg MP, Hartley DM, Choi DW. Non-NMDA receptor-mediated neurotoxicity in cortical culture. J Neurosci 1990;10:693-705.
75. Meden P, Overgaard K, Sereghy T, Boysen G. Enhancing the efficacy of thrombolysis by AMPA receptor blockade with NBQX in a rat embolic stroke model. J Nenro Sci 1993;119:209-16.
76. Sellinger OZ, Garaza A. The inhibition of cerebral glutamine synthetase by structural analogs of the convulsant dl-methionine sulfoximine. Biochem Pharmacol 1966;15:396-9.
77. Swanson RA, Shiraishi K, Morton MT, Sharp FR. Methionine sulfoxamine reduces cortical infarct size in rats after middle cerebral artery occlusion. Stroke 1990;21:322-7.
78. Dunwiddie TV. The physiological role of adenosine in the central nervous system. Int Rev Neurobiol 1985;27:63-139.
79. Fredholm BB, Dunwiddie TV. How does adenosine inhibit transmitter release? Trends Pharmacol Sci 1988;9:130-4.
80. Coradetti R, Lo Conte G, Moroni F, Passani MB, Pepeu G. Adenosine decreases aspartate and glutamate release from rat hippocampal slices. Eur J Pharmacol 1984;104:19-26.
81. Dolphin AC, Archer ER. An adenosine agonist inhibits and a cyclic AMP analogue enhances the release of glutamate but not GABA from slices of rat dentate gyrus. Neurosci Lett 1983;43:49-54.
82. De Leo J, Schubert P, Kreutzberg GW. Propentofylline (HWA 285) protects hippocampal neurons of Mongolian gerbils against ischemic damage in the presence of an adenosine antagonist. Neurosci Lett 1988;84:307-11.
83. De Leo J, Schubert P, Kreutzberg GW. Protection against ischemic brain damage using propentofylline in gerbils. Stroke 1988;19:1535-9.
84. De Leo J, Toth L, Schubert P, Rudolphi K, Kreutzberg GW. Ischemia-induced neuronal cell death. Calcium accumulation and glial response in the hippocampus of the Mongolian gerbil and protection with propentofylline (HWA 285). J Cereb Blood Flow Metab 1987;7:745-51.
85. Dux E, Fastbom J, Ungerstedt U, Rudolphi K, Fredholm BB. Protective effect of adenosine and a novel xanthine derivative propentofylline on the cell damage after bilateral carotid occlusion in the gerbil hippocampus. Brain Res 1990;516:248-56.
86. Grome JJ, Gojowczyk G, Hofmann W. Effect of chronic administration of propentofylline (HWA 285) on the volume of focal ischemic damage in the rat. Stroke 1990;21(suppl 1)I-134-5.
87. Huber M, Kittner B, Hojer C, Fink GR, Neveling M, Heiss WD. Effect of propentophylline on regional cerebral glucose metabolism in acute ischemic stroke. J Cereb Blood Flow Metab 1993;13:526-30.
88. McBurney RN, Daly D, Fisher JB, et al. New specific calcium antagonists. J Neurotrauma 1992;9(suppl 2):531-43.
89. Leach MJ, Swan JH, Eisenthal D, Dopson M, Nobbs M. BW619C89. a glutamate release inhibitor, protects against focal cerebral ischemic damage. Stroke 1993;24:1063-7.
90. Smith SE, Lekieffre D, Sowinski P, Meldrum BS. Cerebroprotective effect of BW619C89 after focal or global cerebral ischaemia in the rat. Neuroreport 1993;4:1339-42.
91. Graham SH, Chen J, Lan J, Leach MJ. Simon RP. Neuroprotective effect of a use-dependent blocker of voltage dependent sodium channels. BW619C89. in rat middle cerebral artery occlusion. J Pharmacol Exp Ther 1994;269:854-9.
92. Fagg GE, Foster AC. Amino acid neurotransmitters and their pathways in the mammalian central nervous system. Neuroscience 1983;9:701-19.
93. Barnard EA, Darlison MG, Fujita N, et al. Molecular biology of the GABA-A receptor. Adv Exp Med Biol 1988;236:31-15.
94. Green AR, Cross AJ, Snape MF, De Souza RJ. The immediate consequences of middle cerebral artery occlusion on GABA synthesis in mouse cortex and cerebellum. Neurosci Lett 1992;138:141-4.
95. Shuaib A, Ijaz S, Hasan S, Kalra J, Gamma-vinyl GABA prevents hippocampal and substantia nigra reticulata damage in repetitive transient forebrain ischemia. Brain Res 1992;590:13-17.
96. Shuaib A, Mazagri R, Ijaz S. GABA agonist "muscimol" is neuroprotective in repetitive transient forebrain ischemia in gerbils. Exp Neurol 1993;123:284-8.
97. A receptor complex in rat brain. Br J Pharmacol 1989;98:284-90.
98. Cross AJ, Jones JA, Baldwin HA, Green AR. Neuroprotective activity of chlormethiazole following transient forebrain ischaemia in the gerbil. Br J Pharmacol 1991;104:406-11.
99. Snape MF, Baldwin HA, Cross AJ, Green AR. The effects of clormethiazole and nimodipine on cortical infarct area after focal cerebral ischaemia in the rat. Neuroscience 1993;53:837-44.
100. 1A agonists; a new therapeutic principle for stroke treatment. Stroke 1990:21 (suppl IV):IV161-3.
101. 1A- receptor agonists on hippocampal damage after transient forebrain ischemia in the Mongolian gerbil. Stroke 1990;21(suppl IV):IV-164-6.
102. 1in cerebral ischemia, Cerebrovasc Brain Metab Rev 1991;3:134-57.
103. Bassi S, Albizzati MG, Sbacchi M, Frattola L, Massarotti M. Double-blind evaluation of monosialoganglioside (GM,) therapy in stroke. J Neurosci Res 1984;12:493-8.
104. 1 ganglioside in cerebrovascular diseases: a double-blind trial in 40 cases. Eur Neurol 1985;24:343-51.
105. 1 ganglioside therapy in acute ischemic stroke. Italian Acute Stroke Study - hemodilution and drug. Stroke 1989;20:1143-9.
106. 1 on acute cerebral ischemia. Acta Neural 1990;12:214-21.
107. 1 in acute stroke. J Neurol Neurosurg Psychiatry 1988;51:1213-14.
108. 1 ganglioside therapy in acute ischemic stroke. Cerebrovasc Dis 1992;2:163-8.
109. Lenzi GL, Grigoletto F, Gent M, et al. Early treatment of stroke with monosialoganglioside GM-1. Efficacy and safety results of the Early Stroke Trial. Stroke 1994;25:1552-8.
110. 1 in acute ischemic stroke: the SASS trial. Stroke 1994;25:1141-8.
111. Yang G, Chan PH, Chen J, et al. Human copperzinc Superoxide dismutase transgenic mice are highly resistant to reperfusion injury after focal cerebral ischemia. Stroke 1994;25:165-70.
112. Xue D, Slivka A, Buchan AM. Tirilazad reduces cortical infarction after temporary but not permanent focal cerebral ischemia in rats. Stroke 1992;23:894-9.
113. The STIPAS investigators. Safety study of tirilazad mesylate in patients with acute ischemic stroke (STIPAS). Stroke 1994;25:418-23.
114. de Courten-Myers GM, Kleinholz M, Wagner KR, Xi G, Myers RE. Efficacious experimental stroke treatment with high-dose methylprednisolone. Stroke 1994;25:487-92.
115. Finkelstein SP, Kemmou A, Caday CG, Berlove DJ. Basic fibroblast growth factor protects cerebrocortical neurons against excitatory amino acid toxicity in vitro. Stroke 1993;24(suppl I):I141-3.
116. Ziehe M, Morbidelli L, Masini E, et al. Nitric oxide mediates angiogenesis in vivo and endothelial cell growth and migration in vitro promoted by substance P. J Clin Int 1994;94:2036-44.
117. 1 reduces infarct size after experimental cerebral ischemia in a rabbit model. Stroke 1993;24:558-62.
118. Linnik MD, Zobrist RH, Hatfield MD. Evidence supporting a role for programmed cell death in focal cerebral ischemia in rats. Stroke 1993;24:2002-9.
119. Chen H, Chopp M, Zhang RL, et al. Anti-CD11b monoclonal antibody reduces ischemic cell damage after transient focal cerebral ischemia in rat. Ann Neurol 1994;35:458-63.
120. Chopp M, Zhang RL, Chen H, Li Y, Jiang N, Rusche JR. Postischemic administration of an anti-Mac-1 antibody reduces ischemic cell damage after transient middle cerebral occlusion in rats. Stroke 1994;25:869-76.
121. Zivin JA, Mazzarella V. Tissue plasminogen activator plus glutamate antagonist improves outcome after embolic stroke. Arch Neurol 1991;48:1235-8.
122. Brott T. Thrombolytic therapy for stroke. Cerebrovasc Brain Metab Rev 1991;3:91-113.
123. Sussmann BJ, Fitch TSP. Thrombolysis with fibrinolysin in cerebral artery occlusion. JAMA 1958;167:1705-9.
124. Marni A, Ferrero ME, Rovati M, Salari PC, Gaja G. Protection of kidney from postischemic reperfusion injury in rats treated with defibrotide. Transplant Proc 1990;22:2226-9.
125. Plucinski TM, Fager RS, Reddy GP. Allosteric interaction of components of the reptilase complex is responsible for enzyme cross inhibition. Mol Pharmacol 1990;38:114-20.
126. del Zoppo GJ. Thrombolytic therapy in cerebrovascular disease. Stroke 1988;19:1174-9.
127. Pessin MS, del Zoppo GJ, Estol CJ. Thrombolytic agents in the treatment of stroke. Clin Neuropharmacol 1990;13:271-89.
128. del Zoppo GJ, Zeumer H, Harker LA. Thrombolytic therapy in stroke: possibilities and hazards. Stroke 1986;17:595-607.
129. 128a. Rentrop P, Blanke H, Karsch KR, Kaiser H, Kostering H, Leitz K. Selective intracoronary thrombolysis in acute myocardial infarction and unstable angina pectoris. Circulation 1981;63:307-17.
130. Reduto LA, Freund GC, Gaeta JM, Smalling RW, Lewis B, Gould KL. Coronary artery reper fusion in acute myocardial infarction: beneficial effects of intracoronary streptokinase on left ventricular salvage and performance. Am Heart J 1981;102:1168-77.
131. Schroder R, Neuhaus KI, Linderer T, Bruggemann T, Tebbe U, Wegscheider K. Impact of late coronary artery reperfusion on left ventricular function one month after acute myocardial infarction (results from the ISAM study). Am J Cardiol 1989;64:878-84.
132. Van de Werf F, Arnold AE. Intravenous tissue plasminogen activator and size of infarct, left ventricular function, and survival in acute myocardial infarction. Br Med J 1988;297:1374-9.
133. GISSI Study Group. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Lancet 1986;1:397-102.
134. Wilcox RG, von der Lippe G, Olsson CG, Jensen G, Skene AM, Hampton JR. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction. Anglo-Scandinavian Study of Early Thrombolysis (ASSET). Lancet 1988;2:525-30.
135. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase. oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;2:349-60.
136. Zeumer H, Hundgen R, Ferbert A, Ringelstein EB. Local intraarterial fibrinolytic therapy in inaccessible internal carotid occlusion. Neuroradiology 1984;26:315-17.
137. del Zoppo GJ, Ferbert A, Otis S, et al. Local intra-arterial fibrinolytic therapy in acute carotid territory stroke: a pilot study. Stroke 1988;19:307-13.
138. Mori E, Tabuchi M, Yoshida T, Yamadori A. Intracarotid urokinase with thromboembolic occlusion of the middle cerebral artery. Stroke 1988;19:802-12.
139. Solis OJ, Roberson GR, Traveras JM, Mohr J, Pessin M. Cerebral angiography in acute cerebral infarction. Revist Interam Radiol 1977;2:19-25.
140. Mohr JP, Caplan LR, Melski JW, et al. The Harvard Cooperative Stroke Registry: a prospective registry. Neurology 1978;28:754-62.
141. Kunitz SC, Gross CR, Heyman A, et al. The pilot Stroke Data Bank: definition, design and data. Stroke 1984;15:740-6.
142. Verstraete M, Collen D. Thrombolytic therapy in the eighties. Blood 1986;67:1529-41.
143. Castellino FJ. A unique enzyme-protein substrate modifier reaction: plasmin/streptokinase interaction. Trends Biochem Sci 1979;4:1-5.
144. Monk JP, Heel RC. Anisoylated plasminogen streptokinase activator complex (APSAC): a review ot its mechanism of action, clinical pharmacology and therapeutic use in acute myocardial infarction. Drugs 1987;34:25-49.
145. Robbins KC, Summaria L, Hsieh B, Shah RJ. The peptide chain ot human plasmin. J Biol Chem 1967;242:2333-42.
146. Rijken DC. Structure/function relationships of t-PA. In: Kluft C, ed. Tissue-type plasminogen activator (t-PA): physiological and clinical aspects. Vol 1. Boca Raton. FL: CRC Press, 1988:101-22.
147. Marder VJ, Sherry S. Thrombolytic therapy: current status. Part 1. N Engl J Med 1988;318:1512-20.
148. Bovill E, Stump D, Tracy R, et al. for the TIMI investigators. Dose response relationship of t-PA infusion to induction of systemic fibrin(ogen)olysis in the thrombolysis in myocardial infarction. (TIMI) trial [Abstract]. Blood 1987:70(suppl 1):367A.
149. Eisenberg PR, Sherman LA, Tiefenbrunn AJ, Ludbrook PA, Sobel BE, Jaffe AS. Sustained fibrinolysis after administration of t-PA despite its short half-life in the circulation. Thromb Haemost 1987;57:35-40.
150. Borer JS. t-PA and the principles of drug approval. N Engl J Med 1987;317:1659-61.
151. White WF, Barlow GH, Mozen MM, The isolation and characterization of plasminogen activators (urokinase) from human urine. Biochemistry 1966;5:2160-9.
152. Bernik MB, Kwaan HC. Plasminogen activator activity in cultures from human tissues. An immunological and histochemical study. J Clin Invest 1969;48:1740-53.
153. Fletcher AP, Alkjaersig N, Sherry S, Genton E, Hirsh J, Bachmann F. The development of urokinase as a thrombolytic agent. Maintenance of a sustained thrombolytic state in man by its intravenous infusion. J Lab Clin Med 1965;65:713-31.
154. Stump DC, Mann KG. Mechanisms of thrombus formation and lysis. Ann Emerg Med 1988;17:1138-47.
155. Gunzler WA, Steffens GJ, Otting F, Buse G, Flohe L. Structural relationship between human high and low molecular mass urokinase. Hoppe Seylers Z Physiol Chem 1982;363:133-41.
156. Lijnen HR, Zamarron C, Blaber M, Winkler ME, Collen D. Activation of plasminogen by pro-urokinase I. Mechanism. J Biol Chem 1986;261:1253-8.
157. Bando H, Okada K, Matsuo O. Thrombolytic effect of pro-urokinase in vitro. Fibrinolysis 1987:1:169-76.
158. Pessin MS. Hemorrhagic transformation in the natural history of acute embolic stroke. In: Hacke W, del Zoppo GJ, Hirschberg M, eds. Thrombolytic therapy in acute ischemic stroke. Berlin: Springer-Verlag, 1991:67-74.
159. Yamaguchi T, Minematsu K, Choki J, Ikeda M. Clinical and neuroradiological analysis of thrombotic and embolic cerebral infarction. Jpn Circ J 1984;48:50-8.
160. Savage M, Fischmann D, Leon M, et al. Efficacy of coronary stents in the treatment of refractory restenosis following balloon angioplasty [Abstract]. J Am Coll Cardiol 1993;32:33A.
161. Molinari GF. Pathogenesis of secondary brain hemorrhage after ischemia: lessons from animal models - and a few from man. too. In: del Zoppo GJ, Mori E, Hacke W, eds. Thrombolytic therapy in acute ischemic stroke II. Heidelberg: Springer-Verlag 1993:29-36.
162. Globus JH, Epstein JA, Green MA, et al. Focal cerebral hemorrhage experimentally induced. J Neuropathol Exp Neural 1949;8:653-70.
163. Globus JH, Epstein JA. Massive cerebral hemorrhage: spontaneous and experimentally induced. J Neuropathol Exp Neurol 1953;12:107-33.
164. Siesjo BK. Pathophysiology and treatment of focal cerebral ischemia. Part I: Pathophysiology. J Neurosurg 1992;77:169-84.
165. Koudstaal PJ, Stibbe J, Vermeulen M. Fatal ischaemic brain oedema after early thrombolysis with tissue plasminogen activator in acute stroke. Br Med J 1988;297:1571-4.
166. del Zoppo, GJ. Microvascular changes during cerebral ischemia and reperfusion. Cerebrovasc Brain Metab Rev 1994;6:47-96.
167. Watson BD. What is the evidence for oxygen radical-mediated reperfusion injury in stroke? In: Ginsberg MD, Dietrich WD, eds. Cerebrovascutar diseases. New York: Raven Press, 1989:381-6.
168. Dalal PM, Shah PM, Sheth SC, Deshparde CK. Cerebral embolism: angiographic observations on a spontaneous clot lysis. Lancet 1965;1:61-4.
169. Irino T, Taneda M, Minami T. Angiographic manifestations in post recanalized cerebral infarction. Neurology 1977;27:471-5.
170. Marier JR. Editorial comment. Stroke 1992;23:1174.
171. Sloan MA. Thrombolytic therapy in experimental focal cerebral ischemia. In: Sawaya R, ed. Fibrinolysis in the central nervous system. Philadelphia: Hanley & Belfus. 1990;177-88.
172. Overgaard K, Sereghy T, Boysen G, Pederson H, Diemer NH. Reduction of infarct volume and mortality by thrombolysis in a rat embolic stroke model. Stroke 1992;23:1167-73.
173. Hirschberg M, Hofferberth B. Rapid fibrinolysis at different time intervals in a canine model of acute stroke [Abstract]. Stroke 1987:18(suppl l):292.
174. Hirschberg M, Hofferberth B. Thrombolytic therapy with urokinase and prourokinase in a canine model of acute stroke [Abstract], Neurology 1987;37(suppl 1):133.
175. De Ley G, Weyne J, Demeester G, et al. Experimental thromboembolic stroke studied by positron emission tomography: immediate versus delayed reperfusion by fibrinolysis. J Cereb Blood Flow Metab 1988;8:539-45.
176. Papadopoulos SM, Chandler WF, Salamat MS, Topol EJ, Sackellares JC. Recombinant human tissue-type plasminogen activator therapy in acute thromboembolic stroke. J Neurosurg 1987;67:394-8.
177. Kissel P, Chehrazi B, Seibert JA, Wagner FC Jr. Digital angiographic quantification of blood flow dynamics in embolie stroke treated with tissue-type plasminogen activator. J Neurosurg 1987;67:399-405.
178. Chehrazi BB, Seibert JA, Kissel P, Hein L, Brock JM. Evaluation of recombinant tissue plasminogen activator in embolie stroke. Neurosurgery 1989;24:355-60.
179. Phillips DA, Fisher M, Smith TW, Davis MA. The safety and angiographic efficacy of tissue plasminogen activator in a cerebral embolization model. Ann Neurol 1988;23:391-4.
180. Lyden PD, Zivin JA, Clark WA, et al. Tissue plasminogen activator-mediated thrombolysis of cerebral emboli and its effect on hemorrhagic infarction in rabbits. Neurology 1989;39:703-8.
181. Watson BD, Prado R, Dietrich MD, et al. Mitigation of evolving cortical infarction in rats by recombinant tissue plasminogen activator following photochemically induced thrombosis. In: Raichle ME, Powers WJ, eds. Cerebrovascular diseases. New York: Raven Press, 1987;317-30.
182. Bednar MM, McAuliffe T, Raymond S, Gross CE. Tissue plasminogen activator reduces brain injury in rabbit model of thromboembolic stroke. Stroke 1990;21:1705-9.
183. Penar PL, Greer CA. The effect of intravenous tissue-type plasminogen activator in a rat model of embolie cerebral ischemia. Yale J Biol Med 198;:60:233-43.
184. Zivin JA, Fisher M, DeGirolami U, Hemenway CC, Stashak JA. Tissue plasminogen activator reduces neurological damage after cerebral embolism. Science 1985;230:1289-92.
185. Zivin JA, Lyden PD, DeGirolami U, et al. Tissue plasminogen activator. Reduction of neurological damage after experimental embolic stroke. Arch Neurol 1988;45:387-91.
186. Slivka A, Pulsinelli W. Hemorrhagic complications of thrombolytic therapy in experimental stroke. Stroke 1987;18:1148-56.
187. Lyden PD, Madden KP, Clark WM, Sasse KC, Zivin JA. Incidence of cerebral hemorrhage with tissue plasminogen activator or streptokinase following embolic stroke in rabbits. Stroke 1990;21:1589-93. [Erratum Stroke 1991;22:285]
188. del Zoppo GJ, Pessin MS, Mori E, Hacke W. Thrombolytic intervention in acute thrombotic and embolic stroke. Semin Neurrol 1991;11:368-84.
189. Brott TG, Haley EC Jr, Levy DE, et al. Urgent therapy for stroke: Part I. Pilot study of tissue plasminogen activator administered within 90 minutes. Stroke 1992;23:632-40.
190. Wityk RJ, Stern BJ. Ischemic stroke: today and tomorrow. Crit Care Med 1994;22:1278-93.
191. Mori E, Yoneda Y, Tabuchi M, et al. Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke. Neurology 1992;42:976-82.
192. Yamaguchi T, Hayakawa T, Kiuchi H. Intravenous tissue plasminogen activator ameliorates the outcome of hyperacute embolic stroke. Cerebrovasc Dis 1993;3:269-72.
193. Haley EC Jr, Levy DE, Brott TG, et al. Urgent therapy for stroke: Part II. Pilot study of tissue plasminogen activator administered 91-180 minutes from onset. Stroke 1992;23:641-5.
194. Abe T, Terashi A, Tohgi H, et al. Clinical efficacy of intravenous administration of SM-9527 (t-PA) in cerebral thrombosis. Clin Eval 1990;18:39-69.
195. Overgaard K, Sperling B, Boysen G, et al. Thrombolytic therapy in acute ischemic stroke. A Danish pilot study. Stroke 1993;24:1439-46.
196. Lee JH, Seo DC, Kim JS, et al. Therapeutic efficacy of urokinase and heparin in acute ischemic stroke [Abstract). Stroke 1994;25:268.
197. Zeumer H, Freilag HJ, Zanella F, Thie A, Arning C. Local intra-arterial fibrinolytic therapy in patients with stroke: urokinase versus recombinant tissue plasminogen activator (t-PA). Neuroradiology 1993;35:159-62.
198. Zeumer H, Freitag HJ, Grzyska U, Neunzig HP. Local intra-arterial fibrinolysis in acute vertebrobasilar occlusion. Technical developments and recent results. Neuroradiology 1989;31:336-40.
199. del Zoppo GJ, Poeck K, Pessin MS, et al. Recombinant tissue plasminogen activator in acute thrombotic and embolie stroke. Ann Neurol 1992;32:78-86.
200. Halbach VV, Higashida RT, Dowd CF, et al. Management of vascular perforations that occur during neurointerventional procedures. AJNR Am J Neuroradiol 1994;15:487-92.
201. Higashida RT, Halbach VV, Dowd CF, et al. Intravascular balloon dilatation therapy for intracranial arterial vasospasm: patient selection, technique and clinical results. Neurosurg Rev 1992;15:89-95.
202. Chapman AB, Rubinstein D, Hughes R, et al. Intracranial aneurysms in autosomal-dominant polycystic kidney disease. N Engl J Med 1992;327:916-20.
203. Mori E, Yoneda Y, Ohksawa S, et al. Double-blind placebo controlled trial of a recombinant tissue plasminogen activator (t-PA) in acute carotid stroke. (Abstract], Neurology 1991:41(suppl 1):347.
204. Yamaguchi T. Intravenous t-PA in acute embolic stroke. In: Hacke W, del Zoppo GJ, Hirschberg M, eds. Thrombolytic therapy in acute ischemic stroke. Heidelberg: Springer-Verlag 1991:168-74.
205. von Kummer R, Hacke W. Safety and efficacy of intravenous tissue plasminogen activator and heparin in acule middle cerebral arlery stroke. Stroke 1992;23:646-52.
206. von Kummer R, Forsting M, Hacke W, et al. Recanalization, infarct volume, cerebral hemorrhage, and clinical outcome after intravenous recombinant tissue plasminogen activator and heparin in acute carotid artery stroke. In: del Zoppo GJ, Mori E, Hacke W, eds. Thrombolytic therapy in acute ischemic stroke II. Heidelberg: Springer-Verlag, 1993:53-8.
207. Brucker AB, Potuschak H, Laich E, et al. Relation of thrombolytic reperfusion and of collateral circulation to outcome in patients suffering cerebral main artery occlusion. In: del Zoppo GJ. Mori E, Hacke W, eds. Thrombolytic therapy in acute ischemic stroke II. Heidelberg: Springer-Verlag. 1993:288-93.
208. Yamaguchi T. Intravenous tissue plasminogen activator in acute thrombotic stroke: a placebocontrolled, double-blind trial. In: del Zoppo GJ, Mori E, Hacke W, eds. Thrombolytic therapy in acute ischemic stroke II. Heidelberg: Springer-Verlag, 1993:59-65.
209. von Kummer R, Forsting M, Sartor K, et al. Intravenous recombinant tissue plasminogen acti vator in acute stroke. In: Hacke W, del Zoppo GJ, Hirschberg M, eds. Thrombolytic therapy in acute ischemic stroke. Heidelberg: Springer-Verlag. 1991:161-7.
210. Hamann G, Haass A, Pidut G, et al. Prourokinase therapy in stroke. In: Hacke W, del Zoppo GJ, Hirschberg M, eds. Thrombolytic therapy in acute ischemic stroke. Heidelberg: Springer-Verlag, 1994:262-5.
211. Ohtaki M, Shinya T, Yamamura A, et al. Local fibrinolytic therapy using superselective catheterization for patients with acute cerebral embolism within 10 hours. In: Tomita M, Mchedlishvili G, Rosenblum W, Heiss W-D, Fukuuchi Y, eds. Microcirculatory stasis in the brain. Amsterdam: Elsevier Science Publishers. 1993;539-45.
212. Fieschi C, Argentino C, Lenzi GL, Sachetti ML, Toni D, Bozzao L. Clinical and instrumental evaluation of patients with ischemic stroke within the first six hours. J Neurol Sci 1989;91:311-21.
213. Matsumoto K, Satoh K. Intra-arterial urokinase infusion for acute stroke. In: Hacke W, del Zoppo GJ, Hirschberg M, eds. Thrombolytic therapy in acute ischemic stroke. Heidelberg: Springer-Verlag, 1991:207-12.
214. Mori E. Fibrinolytic recanalization therapy in acute cerebrovascular thromboembolism. In: Hacke W, del Zoppo GJ, Hirschberg M, eds. Thrombolylic therapy in acute ischemic stroke. Heidelberg: Springer-Verlag, 1991:137-46.
215. Hiramoto M, Yoshimizu N, Satoh K, et al. Intraarterial urokinase therapy in thromboembolic stroke [Abstract]. Stroke 1994;25:268.
216. Wildenhain SL, Jungries CA, Barr J, Mathis J, Wechsler L, Horton JA. CT after intracranial intraarterial thrombolysis for acute stroke. AJNR Am J Neuroradiol 1994;15:487-92.
217. Sugawara Y, Ueda T, Mogami H, Tanada S, Hamamoto K. Intraarterial urokinase infusion therapy with superselective catheterization for acute occlusive cerebrovascular disease. Nippon Acta Radial 1992;52:1083-91.
218. Casto L, Moschini L, Camerlingo M, et al. Local intraarterial thrombolysis for acute stroke in the carotid artery territories. Acta Neurol Scand 1992;86:308-11.
219. Bockenheimer S, Reinhuber F, Mohs C. Intraarterielle Thrombolyse hirnversorgender Gefasse. Radiologe 1991;31:210-15.
220. Moebius E, Berg-Dammer E, Kuhne D, et al. Local thrombolytic therapy in acute basilar artery occlusion. In: Hacke W, del Zoppo GJ, Hirschberg M, eds. Thrombolylic therapy in acute ischemic stroke. Berlin: Springer-Verlag, 1991:213-15.
221. Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: the European Cooperative Acute Stroke Study (ECASS). JAMA 1995;274:1017-25.
222. Boysen G. Anticoagulation for atrial fibrillation and stroke prevention. Neuroepidemiology 1993;12:280-4.
223. The Stroke Prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation: I. Clinical features of patients at risk. Ann Intern Med 1992;116:1-5.
224. The Stroke Prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation: II. Echocardiographic features of patients at risk. Ann Intern Med 1992;116:6-12.
225. The Stroke Prevention in Atrial Fibrillation Investigators. Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation 1991;84:527-39.
226. The Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 1994;343:687-91.
227. Peterson P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet 1989;1:175-8.
228. EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in nonrheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993;342:1255-62.
229. Matchar DB, McCrory DC, Barnett HJM, Feussner JR. Medical treatment for stroke prevention. Ann Intern Med 1994;121:41-53.
230. Barnett HJM, Eliasziw M, Meldrum HE. Drugs and surgery in the prevention of ischemic stroke. N Engl J Med 1995;332:238-48.
231. Reuther R, Dorndorf W. Aspirin in patients with cerebral ischemia and normal angiograms or non-surgical lesions. The results of a double-blind trial. In: Breddin K, Dorndorf W, Loew D, Marx R, eds. Acetylsalicylic acid in cerebral ischemia and coronary heart disease. Stuttgart: Schattauer, 1978:97-106.
232. Fields WS, Lemak NA, Frankowski RF, Hardy RJ. Controlled trial of aspirin in cerebral ischemia. Stroke 1977;8:301-14.
233. Fields WS, Lemak NA, Frankowski RF, Hardy RJ, Bigelow RH. Controlled trial of aspirin in cerebral ischemia. Circulation 1980;62:V90-6.
234. The Canadian Cooperative Study Group. A randomized trial of aspirin and sulfinpyrazone in threatened stroke. N Engl J Med 1978;299:53-9.
235. Bousser MG, Eschwege E, Haguenau M, et al. AICLA controlled trial of aspirin and dipyrimadole in the secondary prevention of athero-thrombotic cerebral ischemia. Stroke 1983;14:5-14.
236. Sorensen PS, Pedersen H.,Marquardsen J, et al. Acetylsalicylic acid in the prevention of stroke in patients with reversible cerebral ischemic attacks. A Danish cooperative study. Stroke 1983;14:15-22.
237. Farrell B, Godwin J, Richards S, Warlow C. The United Kingdom transient ischemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry 1991;54:1044-54.
238. The SALT Collaborative Group. Swedish Aspirin Low-Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. Lancet 1991;338:1345-9.
239. The Swedish Cooperative Study Group. High-dose acetylsalicylic acid after cerebral infarction. A Swedish Cooperative Study. Stroke 1987;18:325-34.
240. The Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg vs. 283 mgaday) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med 1991;325:1261-6.
241. Bornstein NM, Karepov VG, Aronovich BD, Gorbulev AY, Treves TA, Korczyn AD. Failure of aspirin treatment after stroke. Stroke 1994;25:275-7.
242. Grotemeyer KH, Scharafinski HW, Husstedt IW. Two-year follow-up of aspirin responder and aspirin non-responder. Thromb Res 1993;71:397-403.
243. Helgason CM, Bolin KM, Hoff JA, et al. Development of aspirin resistance in persons with previous ischemic stroke. Stroke 1994;25:2331-6.
244. 2 and prostacyclin. Assessment by platelet aggregation testing. Stroke 1992;23:1400-3.
245. Komiya T, Kudo M, Urabe T, Mizuno Y. Compliance with antiplatelet therapy in patients with ischemic cerebrovascular disease. Stroke 1994;25:2337-42.
246. Fields WS, Lemak NA, Frankowski RF, Hardy RJ. Controlled trial of aspirin in cerebral ischemia. Part II: surgical group. Stroke 1978;9:309-19.
247. Boysen G, Sorensen PS, Juhler M, et al. Danish very-low-dose-aspirin after carotid endartereclomy trial. Stroke 1988;19:1211-15.
248. Steering committee of the Physicians' Health Study research group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1989;321:129-35.
249. Peto R, Gray R, Collins R, et al. A randomised trial of the effects of prophylactic daily aspirin among male British doctors. Br Med J 1988;296:313-16.
250. Hennekens CH, Jonas MA, Buring JE. Antiplatelet therapy and risk of stroke. Ann Epidemiol 1993;3:568-70.
251. Manson JE, Stampfer MJ, Colditz GA, et al. A prospective study of aspirin use and primary prevention of cardiovascular disease in women. JAMA 1991;266:521-7.
252. Gent M, Blakely JA, Easton JD, et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989;1:1215-20.
253. Hass WK, Easton JD, Adams HP Jr, et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group. N Engl J Med 1989;321:501-7.
254. Acheson J, Danta G, Hutchinson EC. Controlled trial of dipyrimadole in cerebral vascular disease. Br Med J 1969;1:614-15.
255. Appolonio A, Castignani P, Magrini L, Angeletti R. Ticlopidine-pentoxyfylline combination in the treatment of atherosclerosis and the prevention of cerebrovascular accidents. J Int Med Res 1989;17:28-35.
256. European Stroke Prevention Group. European Stroke Prevention Study. Stroke 1990;21:1122-30.
257. The American-Canadian Co-operative Study Group. Persantine aspirin trial in cerebral ischemia. Part II: Endpoint results. Stroke 1985;16:406-15.
258. Olsson JE, Brechter C, Backlund H, et al. Anticoagulant vs antiplatelet therapy as prophylactic against cerebral infarction in transient ischemic attacks. Stroke 1980;11:4-9.
259. Candelise L, Landi G, Perrone P, Bracchi M, Brambilla G. A randomized trial of aspirin and sulfinpyrazone in patients with TIA. Stroke 1982;13:175-9.
260. Herskovits E, Famulari A, Tamaroff L, et al. Comparative study of pentoxyfylline vs. antiag-gregants in patients with transient ischaemic attacks. Acta Neural Scand Suppl 1989;127:31-5.
261. Gent M, Blakely JA, Hachinski V, et al. A secondary prevention, randomized trial of suloctidil in patients with a recent history of thromboembolic stroke. Stroke 1985;16:416-24.
262. Satoh K, Yoshida H, Imaizumi TA, Koyama M, Hiramoto M, Takamatsu S. Pyrazolopyridine derivative acts as a novel cyclooxygenase inhibitor: antiplatelet effect in aged patients with ischemic stroke. J Am Geriatr Soc 1994;42:639-42.
263. Yao SK, Ober JC, Ferguson JJ, et al. Clopidogrel is more effective than aspirin as adjuvant treatment to prevent reocclusion after thrombolysis. Am J Physiol 1994;267(Pt 2):H488-93.
264. Herbert JM, Tissinier A, Defreyn G, Maffrand JP. Inhibitory effect of clopidogrel on platelet adhesion and intimal proliferation after arterial injury in rabbits. Arterioscler Thromb 1993;13:1171-9.
265. Clopidogrel vs Aspirin in Patients at Risk of Ischemic Events (CAPRIE) [Abstract]. Stroke 1994;25:2113.
266. Brust JC. Transient ischemic attacks: natural history and anticoagulation. Neurology 1977;27:701-7.
267. Sherman DG, Dyken ML, Fisher M, Harrison MJ, Hart RG. Cerebral embolism. Chest 1986;89 (suppl 2):S82-98.
268. Easton JD, Hart RG, Sherman DG, Kaste M. Diagnosis and management of ischemic stroke. Part I. Threatened stroke and its management. Curr Probl Cardiol 1983;8:1-76.
269. Whisnant JP, Matsumoto N, Elveback LR. The effect of anticoagulant therapy on the prognosis of patients with transient cerebral ischemic attacks in a community: Rochester, Minnesota, 1955 through 1969. Mayo Clin Proc 1973;48:844-8.
270. Jonas S. Anticoagulant therapy in cerebrovascular disease: review and meta-analysis. Stroke 1988;19:1043-8.
271. Olsson JE, Brechter C, Backlund H, et al. Anticoagulant vs antiplatelet therapy as prophylactic against cerebral infarction in transient ischemic attacks. Stroke 1980;11:4-9.
272. Buren A, Ygge J. Treatment program and comparison between anticoagulants and platelet aggregation inhibitors after transient ischemic attack. Stroke 1981;12:578-80.
273. Grade A, Samuelsson K, Fahlgren H, Hedberg E, Hjerne LG, Ostman J. Treatment after transient ischemic attacks: a comparison between anticoagulant drug and inhibition of platelet aggregation. Stroke 1983;14:677-81.